GT
CTMX icon

Glenmede Trust’s CytomX Therapeutics CTMX Stock Holding History

Glenmede Trust’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,076
Closed -$7K – 1451
2020
Q3 		$7K Hold
1,076
– – ﹤0.01% 1988
2020
Q2 		$8K Hold
1,076
– – ﹤0.01% 1942
2020
Q1 		$8K Hold
1,076
– – ﹤0.01% 2508
2019
Q4 		$8K Buy
1,076
+185
+21% +$1.25K ﹤0.01% 2508
2019
Q3 		$6 Sell
891
-241
-21% -$2.38K ﹤0.01% 2555
2019
Q2 		$12 Buy
+1,132
New +$11.9K ﹤0.01% 2279

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glenmede Trust's CTMX Position: Q4 2020 in Review

Glenmede Trust sold out of CytomX Therapeutics (CTMX) in Q4 2020, closing a stake of 1,076 shares — an estimated $7K sold.

Glenmede Trust first reported a position in CTMX in Q2 2019 and held it in 6 quarters. The position peaked at $8K in Q2 2020. 126 funds tracked by Wall St. Rank hold CTMX as of Q4 2020.

  • Glenmede Trust reported no remaining CytomX Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 1,076 CytomX Therapeutics shares in Q4 2020, an estimated $7K.
  • Glenmede Trust first reported a position in CytomX Therapeutics in Q2 2019 and held it in 6 quarters.
  • Glenmede Trust's CytomX Therapeutics position peaked at $8K in Q2 2020.
  • 126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.